HB1416 FULLPCS1 Josh West-TJ
2/25/2025 10:24:41 am
COMMITTEE AMENDMENT
HOUSE OF REPRESENTATIVES
State of Oklahoma
SPEAKER:
CHAIR:
I move to amend HB1416
Of the printed Bill
Page Section Lines
Of the Engrossed Bill
By deleting the content of the entire measure, and by inserting in lieu
thereof the following language:
AMEND TITLE TO CONFORM TO AMENDMENTS
Amendment submitted by: Josh West
Adopted: _____________________________
______________________________________
Reading Clerk

1 STATE OF OKLAHOMA
2 1st Session of the 60th Legislature (2025)
3 PROPOSED OVERSIGHT
COMMITTEE SUBSTITUTE
4 FOR
HOUSE BILL NO. 1416 By: West (Josh)
5
6
7
8 PROPOSED OVERSIGHT COMMITTEE SUBSTITUTE
9 An Act relating to non-opioid treatment; defining
terms; authorizing insurers to amend preferred drug
10 lists; allowing for discretion in drug treatment;
prohibiting certain drugs over others for treatment;
11 allowing coverage of drugs once approved by the
United States Food and Drug Administration;
12 authorizing coverage of non-opioid drugs; authorizing
reimbursement to hospitals for non-opioid treatment;
13 providing for codification; and providing an
effective date.
14
15
16 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
17 SECTION 1. NEW LAW A new section of law to be codified
18 in the Oklahoma Statutes as Section 1313.1 of Title 74, unless there
19 is created a duplication in numbering, reads as follows:
20 A. As used in this section:
21 1. "Group insurance plan" means a group insurance plan that
22 covers state employees;
23 2. "Health care prescriber" means an individual authorized by
24 law to prescribe drugs;
Req. No. 12857 Page 1

1 3. "Insurer" means an insurer that offers a group insurance
2 plan; and
3 4. "Non-opioid treatment" means a drug or biological product
4 that is indicated to produce analgesia without acting on the body's
5 opioid receptors, for which there is no other drug or product that
6 is rated as therapeutically equivalent under the Food and Drug
7 Administration's most recent publication of "Approved Drug Products
8 with Therapeutic Equivalence Evaluations".
9 B. Except as otherwise provided in this section, an insurer,
10 for purposes of offering a group insurance plan, may adopt or amend
11 a state preferred drug list (PDL).
12 C. 1. In establishing and maintaining the PDL, the insurer
13 shall ensure that a non-opioid drug approved by the United States
14 Food and Drug Administration for the treatment or management of pain
15 is not disadvantaged or discouraged with respect to coverage
16 relative to an opioid or narcotic drug for the treatment or
17 management of pain on the PDL.
18 2. Paragraph 1 in this subsection does not prohibit an opioid
19 medication from being preferred over other opioid medications, or a
20 non-opioid medication from being preferred over other non-opioid
21 medications.
22 D. This section applies to a non-opioid drug treatment as
23 defined in paragraph 4 of subsection A that has been reviewed and
24 approved for coverage by a group insurance plan or insurer as
Req. No. 12857 Page 2

1 defi ned in subsection A. This section also applies to drugs being
2 provided under a contract between the insurer and a pharmacy
3 benefits manager for purposes of a group insurance plan.
4 SECTION 2. This act shall become effective November 1, 2025.
5
6 60-1-12857 TJ 02/24/25
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Req. No. 12857 Page 3

[DELETED: 2 AS C           O S L           ]
[DELETED:  P B]
[DELETED:  P]
[DELETED:  P T 0]